Doxorubicin - Nippon Kayaku

Drug Profile

Doxorubicin - Nippon Kayaku

Alternative Names: Doxorubicin "NK"; Doxorubicin micelle; Micelle doxorubicin hydrochloride; Micelle-encapsulated doxorubicin; NK 911

Latest Information Update: 22 Dec 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tokyo Womens Medical University
  • Developer Nippon Kayaku
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Lymphoma

Most Recent Events

  • 19 Jul 2013 Biomarkers information updated
  • 07 Jul 2003 Phase-I clinical trials in Cancer in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top